Biospect

About Biospect

From a financial analyst's perspective, Biospect operates in the alternative and complementary medicine technology sector, a market driven by growing consumer interest in holistic health modalities.

The company's primary legal entity is Santévie Sàrl, a Swiss limited liability company established in 2013 and based in Carouge, Switzerland. The firm is directed by its founder, Loïc Lechevalier, who, following years of practice in holistic health, established the company to distribute the Biospect bioresonance device. Lechevalier is also the founder of OdeVie, a business focused on marine plasma products, indicating a broader portfolio within the wellness industry.

Biospect's business model centers on the sale of non-linear system (NLS) bioresonance devices, which are presented as having Russian manufacturing origins. The company targets health practitioners, including naturopaths and holistic therapists, providing them with a tool purported to identify and correct frequency imbalances in the human body. Revenue is generated through the sale of comprehensive packages that bundle the Biospect device with extensive training and after-sales support. One of the key figures associated with the training is Danielle Boussard, a naturopath with extensive experience who lends considerable credibility within the target market.

The core product is the Biospect NLS bioresonance device, such as the Biospect 25. This machine functions by using headset-like sensors to conduct a full-body scan, purportedly measuring the frequency of energy wavelengths from organs, tissues, and cells. The system's software, which contains a database of over 12,000 frequencies, then analyzes these readings to detect deviations from the norm. Following the analysis, the device can be used to deliver corrective frequencies, with the aim of restoring the body's natural energetic balance and stimulating self-regulation. The technology is positioned as a non-invasive method for practitioners to gain insights into potential health disharmonies and to offer supportive therapies. It is important to note that bioresonance is considered a complementary therapy and is not recognized by conventional medicine due to a lack of robust scientific evidence.